A Real-World Analysis of Healthcare Resource Utilization Among Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Treatment with Ravulizumab (EHA 2022) - Apellis Medical Hub

A Real-World Analysis of Healthcare Resource Utilization Among Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Treatment with Ravulizumab

Share Via Email

Back to Conference Resources

PNH Congress Presentations European Hematology Association (EHA) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.